阿司匹林剂量在心血管疾病与糖尿病患者中的比较有效性:ADAPTABLE试验亚组分析
ADAPTABLE试验为开放标签实用性研究,将稳定慢性动脉粥样硬化性心血管疾病(ASCVD)患者随机分配至每日阿司匹林81 mg或325 mg。本预设亚组分析比较合并与不合并糖尿病患者的主要有效性复合终点(全因死亡、心肌梗死住院或卒中住院)和主要安全性终点(大出血住院)。结果显示糖尿病患者风险更高,但81 mg与325 mg阿司匹林在糖尿病患者的有效性终点(9.3% vs 10.0%;HR 0.98 [95% CI 0.83-1.16];P=0.265)和安全性终点(0.87% vs 0.69%;亚分布HR 1.25 [95% CI 0.72-2.16];P=0.772)上均无显著差异。
要点
- 糖尿病患者复合心血管结局发生率高于非糖尿病患者(9.6% vs 5.9%;P<0.001)。
- 糖尿病患者出血事件发生率高于非糖尿病患者(0.78% vs 0.50%;P<0.001)。
- 糖尿病患者中81 mg与325 mg阿司匹林的有效性和安全性终点均无显著差异。
核心结论
- 本研究证实糖尿病患者无论阿司匹林剂量如何均存在固有的较高风险。
- 研究结果提示,即使在高危人群中,较高剂量阿司匹林也未带来额外临床获益。
研究设计与样本
- ADAPTABLE为开放标签实用性研究,将稳定慢性ASCVD患者随机分配至每日阿司匹林81 mg或325 mg。
- 本分析为预设分析,纳入15,076例患者,其中5,676例(39%)有糖尿病,2,820例(49.7%)分配至81 mg,2,856例(50.3%)分配至325 mg。
- 采用Cox比例风险模型比较合并与不合并糖尿病患者的阿司匹林剂量效应。
主要发现
- 糖尿病患者与非糖尿病患者相比,复合心血管结局发生率更高(9.6% vs 5.9%;P<0.001),出血事件发生率也更高(0.78% vs 0.50%;P<0.001)。
- 糖尿病患者中,81 mg与325 mg阿司匹林的主要有效性结局无差异(9.3% vs 10.0%;HR 0.98 [95% CI 0.83-1.16];P=0.265)。
- 糖尿病患者中,81 mg与325 mg阿司匹林的主要安全性结局无差异(0.87% vs 0.69%;亚分布HR 1.25 [95% CI 0.72-2.16];P=0.772)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events. RESEARCH DESIGN AND METHODS: ADAPTABLE, an open-label, pragmatic study, randomized patients with stable, chronic ASCVD to 81 mg or 325 mg of daily aspirin. The effects of aspirin dosing was assessed on the primary effectiveness outcome, a composite of all-cause death, hospitalization for myocardial infarction, or hospitalization for stroke, and the primary safety outcome of hospitalization for major bleeding. In this prespecified analysis, we used Cox proportional hazards models to compare aspirin dosing in patients with and without DM for the primary effectiveness and safety outcome. RESULTS: Of 15,076 patients, 5,676 (39%) had DM of whom 2,820 (49.7%) were assigned to 81 mg aspirin and 2,856 (50.3%) to 325 mg aspirin. Patients with versus without DM had higher rates of the composite cardiovascular outcome (9.6% vs. 5.9%; P < 0.001) and bleeding events (0.78% vs. 0.50%; P < 0.001). When comparing 81 mg vs. 325 mg of aspirin, patients with DM had no difference in the primary effectiveness outcome (9.3% vs. 10.0%; hazard ratio [HR] 0.98 [95% CI 0.83-1.16]; P = 0.265) or safety outcome (0.87% vs. 0.69%; subdistribution HR 1.25 [95% CI 0.72-2.16]; P = 0.772). CONCLUSIONS: This study confirms the inherently higher risk of patients with DM irrespective of aspirin dosing. Our findings suggest that a higher dose of aspirin yields no added clinical benefit, even in a more vulnerable population.
引用
- Narcisse DI, Kim H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. 2024. PMID: 37713477. doi:10.2337/dc23-0749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。